Summary
Vifor Pharma AG (Vifor Pharma), a subsidiary of Galenica Ltd., is a specialty pharmaceutical company which discovers, develops, manufactures, and commercializes prescription and over-the-counter pharmaceutical products for the treatment of iron replacement therapy. The company’s portfolio encompasses products for treatment of iron deficiency, a range of non-prescription products for the treatment of infectious diseases, and iron based phosphate binder for controlling serum phosphorus levels in patients with chronic kidney disease undergoing dialysis. Vifor Pharma’s clinical programs focus on safety and efficacy of Broncho-Vaxom for respiratory tract infections in children and in chronic obstructive pulmonary disease in adults; and Uro-Vaxom for recurrent urinary tract infections. The company holds worldwide rights (excluding Japan) for developing and marketing Roche’s CellCept for auto-immune diseases with the exception of transplants. It also markets third party products. It has manufacturing facilities in Switzerland, the UK and Portugal. Vifor Pharma is headquartered in Glattbrugg, Switzerland.
Vifor Pharma AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Relypsa Raises US$80 Million In Series C Financing 13
Relypsa Secures US$70 Million In Series B Financing Round 15
Relypsa Raises US$4 Million In Venture Financing 17
Partnerships 18
Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 18
Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 19
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 20
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 21
Nycomed International Management Enters Into Distribution Agreement With Vifor Pharma For Intravenous Iron Products 22
Evotec Enters Into Co-Development Agreement With Vifor Pharma 23
Licensing Agreements 24
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 24
Vifor Pharma Enters into Licensing Agreement with ChemoCentryx for CCX168 25
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 27
Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 29
Vifor Pharma Enters into Licensing Agreement with Bitop for Ectoin Allergy Eye Drops and Ectoin Allergy Nasal Sprays 31
Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 32
Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 34
Kissei Pharma Enters Into Licensing Agreement With Vifor Pharma 36
Helsinn Enters Into Licensing Agreement With Vifor Pharma For Gelclair 37
Equity Offering 38
Relypsa Raises USD172 Million in Public Offering of Shares 38
Relypsa Completes Public Offering Of Shares For US$101.2 Million 40
Relypsa Completes IPO For US$86.7 Million 42
Acquisition 44
Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 44
Relypsa May Sell Itself 46
Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 47
Vifor Pharma AG - Key Competitors 48
Key Employees 49
Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
List of Tables
Vifor Pharma AG, Pharmaceuticals & Healthcare, Key Facts 1
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Vifor Pharma AG, Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Vifor Pharma AG, Deals By Therapy Area, 2010 to YTD 2016 9
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 11
Relypsa Raises US$80 Million In Series C Financing 13
Relypsa Secures US$70 Million In Series B Financing Round 15
Relypsa Raises US$4 Million In Venture Financing 17
Helsinn Healthcare Enters into Distribution Agreement with Vifor Pharma for Aloxi 18
Relypsa Enters into Partnership with Vifor-Fresenius Medical Care Renal Pharma 19
Debiopharm Enters Into Co-Marketing Agreement With Vifor Pharma For Pamorelin LA And Salvacyl 20
Probi Enters Into Co-Marketing Agreement With Vifor Pharma 21
Nycomed International Management Enters Into Distribution Agreement With Vifor Pharma For Intravenous Iron Products 22
Evotec Enters Into Co-Development Agreement With Vifor Pharma 23
Vifor Pharma Enters into Licensing Agreement with Pfizer for Retacrit 24
Vifor Pharma Enters into Licensing Agreement with ChemoCentryx for CCX168 25
Vifor Pharma Enters Into Licensing Agreement With Zeria Pharma For Ferinject 27
Helsinn Enters Into Licensing And Distribution Agreement With Vifor Pharma For Netupitant-Palonosetron 29
Vifor Pharma Enters into Licensing Agreement with Bitop for Ectoin Allergy Eye Drops and Ectoin Allergy Nasal Sprays 31
Isotechnika Pharma Enters Into Licensing Agreement With Vifor Pharma For voclosporin 32
Hikma Pharma Enters Into Licensing Agreement With Vifor Pharma For Ferinject 34
Kissei Pharma Enters Into Licensing Agreement With Vifor Pharma 36
Helsinn Enters Into Licensing Agreement With Vifor Pharma For Gelclair 37
Relypsa Raises USD172 Million in Public Offering of Shares 38
Relypsa Completes Public Offering Of Shares For US$101.2 Million 40
Relypsa Completes IPO For US$86.7 Million 42
Galenica Acquires Relypsa for USD1.53 Billion in Tender Offer 44
Relypsa May Sell Itself 46
Galenica Acquires Remaining Stake In Vifor Uriach Pharma From Grupo Uriach 47
Vifor Pharma AG, Key Competitors 48
Vifor Pharma AG, Key Employees 49
Vifor Pharma AG, Subsidiaries 50
List of Figures
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 1
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 1
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 1
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 1
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 6
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2010 to YTD 2016 7
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 8
Vifor Pharma AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 9
